CG Oncology (CGON) Intangibles (2025 - 2026)
CG Oncology (CGON) posted Intangibles of $560000.0 for Q1 2026, down 2.61% on a QoQ basis from $575000.0 in Q4 2025.
CG Oncology (CGON) Intangibles (2025 - 2026) Analysis & Trends
CG Oncology's Intangibles history runs 2 years deep, the most recent figure standing at $560000.0 for Q1 2026.
- Quarterly Intangibles changed N/A year-over-year to $560000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $560000.0 (changed N/A YoY) and the FY2025 annual result came in at $575000.0, changed N/A from the prior year.
- Intangibles was $560000.0 for Q1 2026 at CG Oncology, down from $575000.0 in the prior quarter.
- Across five years, Intangibles topped out at $1.7 million in Q3 2025 and bottomed at $560000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 16.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 11,640.44 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 61.68 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.92 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 418.50 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.29 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 266.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 55.80 Mn |
| 10 | CG Oncology | 6.01 Bn | 6.01 Bn | -1.88 Mn | 560,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 560,000.00 |
| Dec 31, 2025 | 575,000.00 |
| Sep 30, 2025 | 1.70 Mn |